Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: Counterpoint

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 6, Issue 2, 2008, Pages 183-189

  Maertens, Johan ^a   Buvé, Kristel ^a   Anaissie, Elias ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aspergillosis; Azole; Galactomannan; Invasive fungal infection; Preemptive; Prophylaxis

Indexed keywords

ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; FUNGAL DNA; GALACTOSE; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; ASPERGILLOSIS; ASPERGILLUS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; DNA SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL DETECTION; FUNGUS CULTURE; FUNGUS HYPHAE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INCIDENCE; MICROBIOLOGY; MOULD; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; PROPHYLAXIS; REVIEW; ZYGOMYCETES;

EID: 40349114639     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2008.0015     Document Type: Review

References (50)